Premium
Clinical trials update from the Heart Failure Society of America: EMOTE, HERB‐CHF, BEST genetic sub‐study and RHYTHM‐ICD
Author(s) -
Lalukota Krishna,
Cleland John G.F.,
Ingle Lee,
Clark Andrew L.,
Coletta Alison P.
Publication year - 2004
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2004.10.003
Subject(s) - enoximone , medicine , heart failure , inotrope , cardiology , randomized controlled trial , heart rhythm , intensive care medicine
This article summarises key presentations relevant to the pathophysiology, prevention or treatment of heart failure, from the Heart Failure Society of America annual meeting held in Toronto, Canada. Data from the EnoxiMone in intravenous inOTropE‐dependent subjects (EMOTE) study suggest that the oral PDE‐3 inhibitor enoximone may be effective for weaning severe heart failure patients from intravenous inotropic therapy. Hawthorn Extract Randomised Blinded Trial in CHF (HERB‐CHF) failed to show a benefit of hawthorn extract added to conventional heart failure therapy. A genetic sub‐group analysis of the Blocker Evaluation of Survival Trial (BEST) study showed that bucindolol reduced mortality and hospitalisations in patients who were homozygous for the Arg389 variant of the β 1 adrenoceptor. In the Resynchronisation Hemodynamic Treatment for Heart Failure Management (RHYTHM‐ICD) study, patients randomised to cardiac resynchronisation therapy (CRT) showed an improvement in symptoms and functional capacity compared to the control group.